3 completed, 3 enrolling by invitation, 3 recruiting, 2 not yet recruiting. 7 Early Phase 1, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 7 | Recruiting 3, Completed 2, Enrolling by invitation 1, Not yet recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow CorrectSequence Therapeutics Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia CS-121 - Severe Hypertriglyceridemia (sHTG) | Early Phase 1 | Not yet recruiting | CorrectSequence Therapeutics Co., Ltd | 15 | 2026-06-15 | 2026-06-18 |
| A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major CS-101 injection - β-thalassemia Major | Phase 2 | Not yet recruiting | CorrectSequence Therapeutics Co., Ltd | 20 | 2026-04-05 | 2026-03-24 |
| CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia CS-121 - Hyperchylomicronemia | Early Phase 1 | Recruiting | Shanghai Jiao Tong University School of Medicine | 15 | 2026-01-26 | 2026-01-28 |
| CS-121 APOC3 Base Editing in FCS CS-121 - Familial Chylomicronemia Syndrome (FCS) | Early Phase 1 | Recruiting | CorrectSequence Therapeutics Co., Ltd | 15 | 2025-10-15 | 2026-02-11 |
| A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection Beta-Thalassemia | Enrolling by invitation | CorrectSequence Therapeutics Co., Ltd | 8 | 2025-05-15 | 2026-02-10 | |
| A Long-term Follow-up Study in Participants Who Received CS-101 Safety and efficacy assessments - Beta-Thalassemia | Enrolling by invitation | CorrectSequence Therapeutics Co., Ltd | 5 | 2025-01-18 | 2026-02-10 | |
| CS-206 in Patients With Sickle Cell Disease CS-206 - Sickle Cell Disease | Early Phase 1 | Recruiting | CorrectSequence Therapeutics Co., Ltd | 5 | 2024-09-02 | 2026-02-10 |
| A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major CS-101 injection - Beta-Thalassemia Major | Phase 1 | Completed | CorrectSequence Therapeutics Co., Ltd | 9 | 2024-04-18 | 2026-02-10 |
| CS-101 in Patients With β-thalassemia CS-101 - Beta-Thalassemia | Early Phase 1 | Enrolling by invitation | CorrectSequence Therapeutics Co., Ltd | 10 | 2024-03-19 | 2026-06-09 |
| Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia Major CS-101 injection - Beta-Thalassemia | Early Phase 1 | Completed | Children's Hospital of Fudan University | 2 | 2023-11-07 | 2026-05-15 |
| A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia CS-101 - Beta-Thalassemia | Early Phase 1 | Completed | CorrectSequence Therapeutics Co., Ltd | 5 | 2023-08-26 | 2026-02-12 |
beta-Thalassemia (6) · Hypertriglyceridemia (2) · Pancreatitis (2) · Anemia, Sickle Cell (1) · Familial hyperchylomicronemia syndrome (1) · Hyperlipoproteinemia Type I (1)
Safety (1)
China (11)
Yongrong Lai, M.D. (4) · Xiaowen Zhai, M.D. (1) · Yaliang Li (1)